Adipocyte-Targeted Nanotechnology and Cell-Based Therapy for Obesity Treatment.

IF 3.6 4区医学 Q2 CHEMISTRY, MEDICINAL

ChemMedChem Pub Date : 2024-10-10 DOI:10.1002/cmdc.202400611

Yue Wu, Siqi Deng, Siyu Wei, Wenqi Wei, Yunxiang He, Junling Guo

引用次数: 0

Abstract

Obesity is a critical risk factor for the development of metabolic diseases and is often associated with dysfunctional adipocytes. Prevalent treatments such as lifestyle intervention, pharmacotherapy, and bariatric surgery are often accompanied by adverse side effects and poor patient compliance. Nanotechnology and cell-based therapy offer innovative approaches for targeted obesity treatments, as they can directly target adipocytes, regulate lipid metabolism, and minimize off-target effects. Here, we provide an overview of the intricate relationship between adipocytes and obesity, highlighting the potential of nanotechnology and cell-based therapy in obesity treatment. Additionally, we discuss the advancements of adipose-derived mesenchymal stem cells (ADMSCs) in obesity progression, including the latest challenges and considerations for developing adipose-targeted treatments for obesity. The objective is to provide a perspective on the design and development of nanotechnology and cell-based therapy for treating obesity and related comorbidities.

查看原文本刊更多论文

用于治疗肥胖症的脂肪细胞靶向纳米技术和细胞疗法。

肥胖是导致代谢性疾病的重要风险因素，通常与脂肪细胞功能失调有关。普遍的治疗方法，如生活方式干预、药物治疗和减肥手术，往往伴随着不良副作用和患者依从性差等问题。纳米技术和细胞疗法可直接靶向脂肪细胞，调节脂质代谢，并最大限度地减少脱靶效应，因此为肥胖症的靶向治疗提供了创新方法。在此，我们将概述脂肪细胞与肥胖之间错综复杂的关系，重点介绍纳米技术和细胞疗法在肥胖治疗中的潜力。此外，我们还讨论了脂肪间充质干细胞（ADMSCs）在肥胖症进展方面的进展，包括开发脂肪靶向治疗肥胖症的最新挑战和注意事项。目的是为治疗肥胖症及相关合并症的纳米技术和细胞疗法的设计与开发提供一个视角。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.